BORTEZOMIB NEAPOLIS 3.5 MG BT 1

BORTEZOMIB NEAPOLIS, as monotherapy, is indicated for the treatment of patients with progressing multiple myeloma, who have received at least 1 previous treatment and have either benefited or are ineligible for a bone marrow transplant.

BORTEZOMIB NEAPOLIS, in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not eligible for intensive chemotherapy followed by a bone marrow transplant.